Antigen-specific immunotherapies in rheumatic diseases

Area of Science:

• Immunology
• Rheumatology
• Autoimmune Diseases

Background:

• Current therapies for autoimmune and rheumatic diseases manage symptoms but lack curative potential.
• Nonspecific immunosuppression carries risks like increased infection susceptibility.
• Antigen-specific immunotherapy (ASI) aims to target only autoreactive cells, preserving systemic immunity.

Purpose of the Study:

• To review novel approaches for identifying autoepitopes and targeting autoreactive cells for ASI development.
• To summarize promising ASI strategies and their current clinical trial status.

Main Methods:

• Identification of autoepitopes and autoreactive cells.
• Development of tolerizing peptides, MHC constructs, nanocompounds, tolerizing dendritic cells, and antigen-specific vaccines.
• Evaluation in animal models of rheumatoid arthritis and systemic lupus erythematosus.

Main Results:

• Several ASI strategies have shown promise in preclinical studies.
• Some novel ASI approaches have progressed to human clinical trials.
• Challenges remain in selecting autoantigens, optimizing administration, and monitoring therapy.

Conclusions:

• ASI represents a promising, targeted approach for autoimmune and rheumatic diseases.
• Further research is needed to overcome limitations for successful human application.
• Successful ASI could lead to disease-specific, curative treatments.